News story
Avanafil's Positive News
Posted: Friday, 20 May, 2011 | Categories: erectile dysfunction
Phase III results from the avanafil trials were announced this week and the outlook is positive. The results were presented at the 2011 Annual Meeting of the American Urological Association in Washington.
It was reported that 80% of endeavours resulted in erections suffice for intercourse. (This was all measured against the Sexual Encounter Profile and the International Index of Erectile Dysfunction).
The previously reported safety and efficacy of the drug in previous trials’ I and II were cemented by this phase III trial.
Furthermore, intercourse was possible within 15 minutes of taking the drug and the drug was well received since the number of people dropping out of the trial was very low at less than 3%. This will be due to moderate side effects and the quality of the drug’s effects.
With the market becoming increasingly competitive now that Pfizer have run out of time on their Viagra patent, newer PDE5 inhibitors with an added something like the 15 minute activation period associated with avanafil will really boost a company’s sales and popularity in a highly cut throat pharmaceutical industry. Headache, flushing and nasal congestion were among the minor side effects reported as is generally reported alongside most erectile dysfunction treatments that are already on the market. These side effects should be monitored though by the doctor who prescribed them in order to assess the effects of the drug on the patient in accordance with the medical health details collected.
Categories
- Erectile Dysfunction (5)
- Treatments (1)
- Cialis (1)
- Viagra (2)
- erectile dysfunction (7)
- treatments (1)
- New Treatments (1)
- Priapism (1)
- Premature Ejaculation (1)
- smoking (1)
- viagra cialis levitra (1)
- viagra (2)
- niacin (1)
- erectile dysfunction (1)
- bowel cancer (1)
- erectile dysfunction (1)
- NHS (1)
- Viagra (1)